Ftse Mib
33.031,16
-0,59%
DAX
18.974,27
-0,14%
S&P 500
5.917,11
0,00%
NASDAQ
18.966,14
-0,11%
Bitcoin
97.938,49
3,79%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kura Oncology Inc (KURA) Kura Oncology Inc (KURA) Notizie

Kura Oncology Inc

KURA
14,00
-1,91 (-12,01%)
Pre Mercato
Ultimo aggiornamento: 11:27:30
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
20/11/202423:21EDGAR2Form 8-K - Current report
20/11/202423:00PRNUSKura Oncology and Kyowa Kirin Announce Global Strategic..
19/11/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18/11/202422:03EDGAR2Form 144 - Report of proposed sale of securities
07/11/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202422:10EDGAR2Form 8-K - Current report
07/11/202422:05GLOBEKura Oncology Reports Third Quarter 2024 Financial Results
05/11/202415:09GLOBEKura Oncology to Present Updated Data from KOMET-007..
31/10/202412:30GLOBEKura Oncology to Report Third Quarter 2024 Financial Results
24/10/202413:30GLOBEKura Oncology Reports Preclinical Data Supporting..
23/10/202413:30GLOBEKura Oncology to Present New Data Supporting Combination of..
01/10/202400:30GLOBEKura Oncology Announces Publication of Ziftomenib Phase 1..
17/9/202422:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
17/9/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/9/202422:05EDGAR2Form 8-K - Current report
17/9/202413:30GLOBEKura Oncology Appoints Michael Vasconcelles, M.D., to Board..
10/9/202413:30GLOBEKura Oncology to Participate in Cantor Global Healthcare..
08/8/202422:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202422:10EDGAR2Form 8-K - Current report
08/8/202422:05GLOBEKura Oncology Reports Second Quarter 2024 Financial Results
08/8/202413:30GLOBEKura Oncology Announces FDA Clearance of IND Application for..
01/8/202413:30GLOBEKura Oncology to Report Second Quarter 2024 Financial..
05/7/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
24/6/202413:30GLOBEKura Oncology Reports Preclinical Data Supporting Potential..
07/6/202422:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
07/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/6/202422:05EDGAR2Form 8-K - Current report
07/6/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
29/5/202413:30GLOBEKura Oncology to Participate in Jefferies Global Healthcare..
24/5/202422:06EDGAR2Form 8-K - Current report
21/5/202400:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/5/202422:19EDGAR2Form 144 - Report of proposed sale of securities
14/5/202413:30GLOBEKura Oncology Completes Enrollment in Registration-Directed..
08/5/202413:30GLOBEKura Oncology to Participate in Bank of America Securities..
03/5/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
02/5/202422:05GLOBEKura Oncology Reports First Quarter 2024 Financial Results
25/4/202413:30GLOBEKura Oncology to Report First Quarter 2024 Financial Results
22/4/202413:30GLOBEKura Oncology Receives Breakthrough Therapy Designation for..
10/4/202413:30GLOBEKura Oncology to Participate in Stifel Targeted Oncology..
05/4/202413:30GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
06/3/202413:30GLOBEKura Oncology Reports First Patient Dosed in Trial of..
01/3/202423:00GLOBEKura Oncology Reports Inducement Grants Under Nasdaq Listing..
27/2/202422:52EDGAR2Form S-8 - Securities to be offered to employees in employee..
27/2/202422:03EDGAR2Form 8-K - Current report
27/2/202422:01GLOBEKura Oncology Reports Fourth Quarter and Full Year 2023..
26/2/202413:30GLOBEKura Oncology Doses First Patient in KOMET-008 Trial of..
22/2/202413:30GLOBEKura Oncology to Participate in Three Upcoming Investor..
20/2/202413:30GLOBEKura Oncology to Report Fourth Quarter and Full Year 2023..
15/2/202422:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
Apertura: Min: Max:
Chiusura: 15,91

La tua Cronologia

NASDAQ
KURA
Kura Oncology
ASX
PNI
Pinnacle Investment Mana...
LSE
YNGA
Young & Co's Brewery
FX
NZDUSD
NZD vs US Dollar
LSE
AVG
Avingtrans
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network